PF-184563 is a potent, selective non-peptidic antagonist of the
V1a receptor.[1] The compound was discovered by
Pfizer in its
Sandwich, Kent research center, as a potential treatment for
dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.[2]
References
^Johnson PS, Ryckmans T, Bryans J, Beal DM, Dack KN, Feeder N, Harrison A, Lewis M, Mason HJ, Mills J, Newman J, Pasquinet C, Rawson DJ, Roberts LR, Russell R, Spark D, Stobie A, Underwood TJ, Ward R, Wheeler S (October 2011). "Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability". Bioorg. Med. Chem. Lett. 21 (19): 5684–5687.
doi:
10.1016/j.bmcl.2011.08.038.
PMID21885275.
^Brouard R, Bossmar T, Fournie-Lloret D, Chassard D, Akerlund M (2000). "Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea". Br. J. Obstet. Gynaecol. 107 (5): 614–619.
doi:
10.1111/j.1471-0528.2000.tb13302.x.
PMID10826575.
S2CID19439985.